Depression is common in HIV-infected patients receiving antiretroviral therapy. However, longitudinal studies addressing the role that depression might play in HIV clinical progression and mortality remain rare. This is especially true for those studies that also consider the possible confounding influence of patient's adherence to treatment.
Methods
The ANRS CO-8 APROCO-COPILOTE cohort study enrolled 1,281 individuals at the initiation of a protease-inhibitor-containing regimen between 1997 and 1999. Adherence, depressive symptoms and other psychosocial factors were measured using self-administered questionnaires. Predictors of progression to AIDS or death were studied using Cox models.
Results
Out of 1,028 individuals eligible for the present analysis, 92 individuals either died or had an AIDS-defining event during a median follow up of 54 months. At baseline, 377 individuals (41%) reported depressive symptoms and 124 (12%) reported non-adherence at month 4. Depressive symptoms at baseline were associated with progression (hazard ratio [HR] 2.1; P=0.001). Despite the association between depressive symptoms and non-adherence, depressive symptoms remained a predictor of clinical progression (adjusted HR [aHR] [95% confidence interval (CI)] 1.6 [1.0–2.5]) after adjustment for several factors: initial non-adherence (aHR [95% CI] 2.0 [1.1–3.6]), having a steady partner (aHR [95% CI] 0.5 [0.3–0.7]), older age (aHR [95% CI] 1.40 [1.12–1.74] per 10-year increment), HIV clinical stage C (aHR [95% CI] 2.5 [1.6–4.0]), plasma HIV RNA ≥100,000 copies/ml (aHR [95% CI] 1.7 [1.1–2.87]) and more than 8 years since HIV diagnosis (aHR [95% CI] 1.8 [1.1–2.8]).
Conclusion
Depressive symptoms and non-adherence are independent predictors of HIV clinical progression and mortality. Screening and appropriate treatment of depressive symptoms at antiretroviral treatment initiation should be included in the standard care of HIV-infected patients.
References
1.
RimarL., RimarD.[Depression, myocardial infarction and the immune system - the chicken before the egg problem].Harefuah2004; 143: 73–78, 83.
2.
SpiegelD., Giese-DavisJ.Depression and cancer: mechanisms and disease progression.Biol Psychiatry2003; 54: 269–282.
3.
MaddockC., ParianteC.M.How does stress affect you? An overview of stress, immunity, depression and disease.Epidemiol Psichiatr Soc2001; 10: 153–162.
4.
LesermanJ.HIV disease progression: depression, stress, and possible mechanisms.Biol Psychiatry2003; 54: 295–306.
5.
MayneT.J., VittinghoffE., ChesneyM.A., BarrettD.C., CoatesT.J.Depressive affect and survival among gay and bisexual men infected with HIV.Arch Intern Med1996; 156: 2233–2238.
6.
LesermanJ., JacksonE.D., PetittoJ.M., GoldenR.N., SilvaS.G., PerkinsD.O.Progression to AIDS: the effects of stress, depressive symptoms, and social support.Psychosom Med1999; 61: 397–406.
7.
LesermanJ., PetittoJ.M., GoldenR.N.Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS.Am J Psychiatry2000; 157: 1221–1228.
8.
PattersonT.L., SempleS.J., TemoshokL.R.Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. HIV Neurobehavioral Research Center Group.Psychiatry1995; 58: 299–312.
9.
IckovicsJ.R., HamburgerM.E., VlahovD.Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study.JAMA2001; 285: 1466–1474.
10.
CookJ.A., GreyD., BurkeJ., CohenM.H., GurtmanA.C., RichardsonJ.L.Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.Am J Public Health2004; 94: 1133–1140.
11.
BouhnikA.D., PreauM., VincentE.Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.Antivir Ther2005; 10: 53–61.
12.
AnastosK., SchneiderM.F., GangeS.J.The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women.J Acquir Immune Defic Syndr2005; 39: 537–544.
13.
PenceB.W., MillerW.C., GaynesB.N., EronJ.J.Jr.Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.J Acquir Immune Defic Syndr2007; 44: 159–166.
14.
CarrieriM.P., RaffiF., LewdenC.Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.Antivir Ther2003; 8: 585–594.
15.
WoodE., HoggR.S., YipB., HarriganP.R., O‘ShaughnessyM.V., MontanerJ.S.Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.Ann Intern Med2003; 139: 810–816.
16.
StaraceF., AmmassariA., TrottaM.P.Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy.J Acquir Immune Defic Syndr2002; 31Suppl 3: S136–S139.
17.
PhillipsK.D., MoneyhamL., MurdaughC.Sleep disturbance and depression as barriers to adherence.Clin Nurs Res2005; 14: 273–293.
18.
TurnerB.J., LaineC., CoslerL., HauckW.W.Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users.J Gen Intern Med2003; 18: 248–257.
19.
FuhrerR., RouillonF.La version française de l‘échelle CES-D (Center for Epidemiologic Studies Depression Scale). Description et traduction de l'échelle d'autoévaluation. [Description and translation of the autoevaluation scale.] Psychiatrie et Psychobiologie1989; 4: 163–166. French.
20.
CarrieriP., CailletonV., Le MoingV.The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort.J Acquir Immune Defic Syndr2001; 28: 232–239.
21.
ChesneyM.A., IckovicsJ.R., ChambersD.B.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).AIDS Care2000; 12: 255–266.
22.
YoungJ., De GeestS., SpirigR.Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.BMJ2004; 328: 15.
23.
ChowK.Y., AngL.W., VerghesseI., ChewS.K., LeoY.S.Measurable predictive factors for progression to AIDS among HIV-infected patients in Singapore.Ann Acad Med Singapore2005; 34: 84–89.
24.
CruessD.G., DouglasS.D., PetittoJ.M.Association of depression, CD8+ T lymphocytes, and natural killer cell activity: implications for morbidity and mortality in Human immunodeficiency virus disease.Curr Psychiatry Rep2003; 5: 445–450.
25.
CruessD.G., PetittoJ.M., LesermanJ.Depression and HIV infection: impact on immune function and disease progression.CNS Spectr2003; 8: 52–58.
26.
BangsbergD.R., PerryS., CharleboisE.D.Non-adherence to highly active antiretroviral therapy predicts progression to AIDS.AIDS2001; 15: 1181–1183.
27.
Garcia de OlallaP., KnobelH., CarmonaA., GuelarA., Lopez-ColomesJ.L., CaylaJ.A.Impact of adherence adn highly active antiretroviral therapy on survival in HIV-infected patients.J Acquir Immune Defic Syndr2002; 30: 105–110.
28.
LiebS., BrooksR.G., HopkinsR.S.Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics.J Acquir Immune Defic Syndr2002; 30: 351–358.
29.
WoodE., MontanerJ.S., ChanK.Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.AIDS2002; 16: 2065–2072.
30.
LewdenC., BonnetF., BevilacquaS.Causes de décès chez les usagers de drogues français infectés par le VIH, 1995–2000. [Causes of death in HIV-infected French drug users, 1995–2000].Ann Med Interne (Paris)2002; 153: 2S4–10. French.
31.
GrabarS., Le MoingV., GoujardC.Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection.J Acquir Immune Defic Syndr2005; 39: 284–292.
32.
Friis-MollerN., WeberR., ReissP.Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study.AIDS2003; 17: 1179–1193.
33.
CarrieriM.P., LeportC., ProtopopescuC.Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase.J Acquir Immune Defic Syndr2006; 41: 477–485.
34.
DuranS., SpireB., RaffiF.Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAARTHIV Clin Trials2001; 2: 38–45.
35.
PradierC., BentzL., SpireB.Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study.HIV Clin Trials2003; 4: 121–131.
